Sommetrics, a company providing products and services to improve sleep quality, has engaged Key West Investments to help raise additional capital. This capital will support the company’s development and commercialization of products to treat disorders of the upper airway such as obstructive sleep apnea and chronic snoring.

“Our mission is to improve the quality of sleep for people worldwide,” says Richard Rose, MD, Sommetrics’ CEO and board chair, in a release. “Sommetrics has an opportunity to substantially disrupt the sleep industry with its patented technology and bring leading-edge therapy to those around the globe who suffer from breathing disorders such as sleep apnea. Partnering with Key West Investments is a vital step in raising the capital needed to carry out this mission.”

Key West Investments offers a wide range of financial and business advisory services for both public or private entities. Its services range from financial analysis, valuation, and capital raising to IPO management and mergers and acquisitions.

“Interrupted sleep and snoring are major problems for so many people,” says Yvonne Yiu, Key West Investments’ president and CEO. “We look forward to helping them raise the necessary capital to turn this opportunity into a reality.”

Earlier this year, Sommetrics announced its sleep apnea therapy system, aerSleep, received Health Canada approval, allowing it to be marketed in Canada. aerSleep uses negative external air pressure to treat obstructive sleep apnea.

Sommetrics also recently partnered with Smiths Medical to distribute its aerFree Airway Management System (AMS), the first FDA-cleared external negative pressure aid that maintains a patent upper airway during mild to moderate sedation. The launch has been initiated in select US markets and a global launch will follow in 2018.